Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial.

Ruperto N, Lovell DJ, Synoverska O, Abud-Mendoza C, Spindler A, Vyzhga Y, Reyhan I, Grebenkina L, Tirosh I, Imundo L, Chiraseveenuprapund P, Kingsbury DJ, Sozeri B, Vora SS, Prahalad S, Zholobova E, Roberts KD, Sawyerr G, Blum A, Shapiro A, Diehl A, Ebrahim A, Klaus P, Martini A, Brunner HI, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

Open source

DOI
10.1002/acr2.70097
Published
2025 Oct
Container
ACR open rheumatology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/acr2.70097,
  title = {Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial.},
  author = {Ruperto N and Lovell DJ and Synoverska O and Abud-Mendoza C and Spindler A and Vyzhga Y and Reyhan I and Grebenkina L and Tirosh I and Imundo L and Chiraseveenuprapund P and Kingsbury DJ and Sozeri B and Vora SS and Prahalad S and Zholobova E and Roberts KD and Sawyerr G and Blum A and Shapiro A and Diehl A and Ebrahim A and Klaus P and Martini A and Brunner HI and Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)},
  year = {2025},
  journal = {ACR open rheumatology},
  doi = {10.1002/acr2.70097},
  url = {https://doi.org/10.1002/acr2.70097}
}

RIS

TY  - JOUR
TI  - Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial.
AU  - Ruperto N
AU  - Lovell DJ
AU  - Synoverska O
AU  - Abud-Mendoza C
AU  - Spindler A
AU  - Vyzhga Y
AU  - Reyhan I
AU  - Grebenkina L
AU  - Tirosh I
AU  - Imundo L
AU  - Chiraseveenuprapund P
AU  - Kingsbury DJ
AU  - Sozeri B
AU  - Vora SS
AU  - Prahalad S
AU  - Zholobova E
AU  - Roberts KD
AU  - Sawyerr G
AU  - Blum A
AU  - Shapiro A
AU  - Diehl A
AU  - Ebrahim A
AU  - Klaus P
AU  - Martini A
AU  - Brunner HI
AU  - Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
PY  - 2025
JO  - ACR open rheumatology
DO  - 10.1002/acr2.70097
UR  - https://doi.org/10.1002/acr2.70097
ER  - 

APA

N, R., DJ, L., O, S., C, A., A, S., Y, V., I, R., L, G., I, T., L, I., P, C., DJ, K., B, S., SS, V., S, P., E, Z., KD, R., G, S., A, B., A, S., A, D., A, E., P, K., A, M., HI, B., & (PRCSG), P. R. I. T. O. (. A. T. P. R. C. S. G. (2025). Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial.. ACR open rheumatology. https://doi.org/10.1002/acr2.70097

Source records